Search form

Search form

Eisai has sold the U.S. rights to Targretin capsules and 1% gel to Valeant Pharmaceuticals for $65 million plus possible milestone fees. Valeant will handle the new drug application and other regulatory obligations in the U.S. Targretin, or bexarotene, capsules and gel are used to treat patients with skin problems associated with cutaneous T-cell lymphoma who failed to respond to at least one systemic treatment.

Related Summaries

Bexarotene capsules, a generic version of Valeant Pharmaceuticals' Targretin capsules, have been launched in the U.S. by Mylan as a treatment for cutaneous manifestations of cutaneous T-cell lymphoma for patients who have received at last previous systemic treatment.

A Series B funding round has pulled in $65 million for Dimension Therapeutics, a gene therapy firm in Cambridge, Mass. The company plans to conduct a clinical trial this year using its gene therapy delivery technology for the treatment of hemophilia B.

Massachusetts-based Histogenics plans to launch an initial public offering in a quest to obtain as much as $65 million. The company is preparing to conduct a late-stage study of its NeoCart regenerative medicine system, designed to help treat patients with damaged or degenerated knee joint cartilage.

Banner Pharmacaps said the FDA accepted for review the firm's 75-milligram bexarotene softgel capsule. The drug, a generic version of Eisai's Targretin, is indicated for cutaneous T-cell lymphoma. Banner can claim 180-day market exclusivity if its product is approved.

NIH's National Heart, Lung, and Blood Institute is allotting $65 million to revive its Programs for Nanotechnology Research project, which was started in 2005. The initiative aims to advance the development of nanotechnologies that can be used to improve the diagnosis and treatment of heart, lung and blood diseases. The funds will be given out to four interdisciplinary teams across the U.S. over a five-year period.